News

Novocure (NASDAQ: NVCR) today reported preliminary unaudited financial results and operational updates for the quarter and full year ended December 31, 2023. Novocure is a global oncology company

ICON plc, (NASDAQ: ICLR) a world-leading healthcare intelligence and clinical research organisation, today launched its “Optimising biotech funding” whitepaper. This provides an overview of the

NanoString Technologies, Inc. (Nasdaq: NSTG), a leading provider of life science tools for discovery and translational research, today announced, as required by Nasdaq Stock Market Rules, equity

Agilent Technologies Inc. (NYSE: A) today announced the company has again been included in the Dow Jones Sustainability World Index and the North America Index for its strong environmental, social

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today provided an update on its 2023 fourth quarter and full year business performance. Preliminary unaudited net product

Novocure (NASDAQ: NVCR) today announced the appointment of Nicolas Leupin, M.D., Ph.D., MBA to the role of Chief Medical Officer. Dr. Leupin brings a proven track record of leadership and

LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, will host a conference call to discuss its fourth-quarter and full-year 2023 results on Wednesday, February 21, 2024 at 1

Premier, Inc. (NASDAQ: PINC), a leading technology-driven healthcare improvement company, today announced that members of its management team will participate in the J.P. Morgan Healthcare

ICON plc, (NASDAQ: ICLR) a world-leading healthcare intelligence and clinical research organization, today announced that Dr. Steve Cutler, CEO of ICON plc, will present at the 42^nd Annual J.P

NanoString Technologies, Inc. (NASDAQ:NSTG), a leading provider of life science tools for discovery and translational research, today announced that company management is scheduled to webcast a

Simulations Plus, Inc. (NASDAQ: SLP) (“Simulations Plus”), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today reported financial

Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today announced the following

Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced that

Regulatory News:

POXEL SA (Euronext: POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic

Acadia Healthcare Company, Inc. (NASDAQ: ACHC) today announced that the Company will present at the 42nd Annual J.P. Morgan Healthcare Conference, January 8-11, 2024, at The Westin St. Francis, San

Pfizer Inc. (NYSE: PFE) invites investors and the general public to listen to a webcast of a discussion with Albert Bourla, Chairman and Chief Executive Officer, at the 42^nd Annual J.P. Morgan

Pfizer Inc. (NYSE: PFE) invites investors and the general public to listen to a webcast of a discussion with Albert Bourla, Chairman and Chief Executive Officer, at the 42^nd Annual J.P. Morgan

Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced that Dane

Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous

Novocure (NASDAQ: NVCR) announced today that management will participate in the 42^nd Annual J.P. Morgan Healthcare Conference on January 9-10, 2024. William Doyle, Novocure’s Executive Chairman